• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病的计算机建模及其透明度:第八届胡德山挑战赛报告。

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.

机构信息

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

出版信息

Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.

DOI:10.1016/j.jval.2018.02.002
PMID:29909878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6659402/
Abstract

OBJECTIVES

The Eighth Mount Hood Challenge (held in St. Gallen, Switzerland, in September 2016) evaluated the transparency of model input documentation from two published health economics studies and developed guidelines for improving transparency in the reporting of input data underlying model-based economic analyses in diabetes.

METHODS

Participating modeling groups were asked to reproduce the results of two published studies using the input data described in those articles. Gaps in input data were filled with assumptions reported by the modeling groups. Goodness of fit between the results reported in the target studies and the groups' replicated outputs was evaluated using the slope of linear regression line and the coefficient of determination (R). After a general discussion of the results, a diabetes-specific checklist for the transparency of model input was developed.

RESULTS

Seven groups participated in the transparency challenge. The reporting of key model input parameters in the two studies, including the baseline characteristics of simulated patients, treatment effect and treatment intensification threshold assumptions, treatment effect evolution, prediction of complications and costs data, was inadequately transparent (and often missing altogether). Not surprisingly, goodness of fit was better for the study that reported its input data with more transparency. To improve the transparency in diabetes modeling, the Diabetes Modeling Input Checklist listing the minimal input data required for reproducibility in most diabetes modeling applications was developed.

CONCLUSIONS

Transparency of diabetes model inputs is important to the reproducibility and credibility of simulation results. In the Eighth Mount Hood Challenge, the Diabetes Modeling Input Checklist was developed with the goal of improving the transparency of input data reporting and reproducibility of diabetes simulation model results.

摘要

目的

第八届胡德山挑战赛(2016 年 9 月在瑞士圣加仑举行)评估了两项已发表的健康经济学研究的模型输入文件的透明度,并制定了改善基于模型的经济学分析中输入数据报告透明度的指南,该分析以糖尿病为研究对象。

方法

要求参与建模的小组使用文章中描述的输入数据重现两项已发表研究的结果。通过建模小组报告的假设来填补输入数据中的空白。使用线性回归线的斜率和确定系数(R)评估目标研究中报告的结果与小组复制结果之间的拟合优度。在对结果进行一般性讨论之后,制定了一个用于糖尿病模型输入透明度的检查表。

结果

有 7 个小组参加了透明度挑战赛。两项研究中关键模型输入参数的报告,包括模拟患者的基线特征、治疗效果和治疗强化阈值假设、治疗效果演变、并发症预测和成本数据,不够透明(而且经常完全缺失)。毫不奇怪,报告输入数据更透明的研究的拟合优度更好。为了提高糖尿病建模的透明度,制定了糖尿病建模输入检查表,列出了大多数糖尿病建模应用程序中重现所需的最小输入数据。

结论

糖尿病模型输入的透明度对于模拟结果的可重复性和可信度很重要。在第八届胡德山挑战赛中,制定了糖尿病建模输入检查表,旨在提高输入数据报告的透明度和糖尿病模拟模型结果的可重现性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50b/6659402/afcfeff2e7c6/nihms-1037199-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50b/6659402/a5df4937c176/nihms-1037199-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50b/6659402/afcfeff2e7c6/nihms-1037199-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50b/6659402/a5df4937c176/nihms-1037199-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a50b/6659402/afcfeff2e7c6/nihms-1037199-f0002.jpg

相似文献

1
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.糖尿病的计算机建模及其透明度:第八届胡德山挑战赛报告。
Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9.
2
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.健康经济决策模型中的透明度和验证挑战:来自胡德山的观点。
Pharmacoeconomics. 2019 Nov;37(11):1305-1312. doi: 10.1007/s40273-019-00825-1.
3
Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge.探索健康状态效用值在糖尿病经济模拟模型中的结构不确定性及其对终生结局的影响:来自第九次胡德山糖尿病生活质量挑战赛的结果。
Med Decis Making. 2022 Jul;42(5):599-611. doi: 10.1177/0272989X211065479. Epub 2021 Dec 15.
4
Economic Simulation Modeling in Type 2 Diabetes.2 型糖尿病的经济模拟建模。
Curr Diab Rep. 2020 May 17;20(7):24. doi: 10.1007/s11892-020-01306-y.
5
Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.糖尿病及其并发症的计算机建模:第五届胡德山挑战赛会议报告。
Value Health. 2013 Jun;16(4):670-85. doi: 10.1016/j.jval.2013.01.002. Epub 2013 Apr 18.
6
Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.糖尿病及其并发症的计算机建模:胡德山挑战赛第四次会议报告
Diabetes Care. 2007 Jun;30(6):1638-46. doi: 10.2337/dc07-9919.
7
Cost-effectiveness of an electronic medical record based clinical decision support system.基于电子病历的临床决策支持系统的成本效益分析。
Health Serv Res. 2012 Dec;47(6):2137-58. doi: 10.1111/j.1475-6773.2012.01427.x. Epub 2012 May 11.
8
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.比较队列和微观模拟模型在 2 型糖尿病成本效益建模中的应用:以 IHE 糖尿病队列模型和 T2DM 经济学和健康结局模型为例。
Pharmacoeconomics. 2020 Sep;38(9):953-969. doi: 10.1007/s40273-020-00922-6.
9
TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility.技术验证:减少模型错误并提高其可信度的验证清单。
Pharmacoeconomics. 2019 Nov;37(11):1391-1408. doi: 10.1007/s40273-019-00844-y.
10
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge.审视 10 种 2 型糖尿病模型中的结构不确定性的影响:来自 2022 年胡德山挑战赛的结果。
Value Health. 2024 Oct;27(10):1338-1347. doi: 10.1016/j.jval.2024.06.010. Epub 2024 Jul 8.

引用本文的文献

1
Reproducibility of published model-based cancer drug cost-effectiveness analyses: a study protocol for a cross-sectional analysis.已发表的基于模型的癌症药物成本效益分析的可重复性:一项横断面分析的研究方案
BMJ Open. 2025 Jun 20;15(6):e096719. doi: 10.1136/bmjopen-2024-096719.
2
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.胰岛素治疗的卫生经济学:我们如何应对不断增长的需求、成本、不平等现象以及实现最佳治疗效果的障碍。
Diabetes Obes Metab. 2025 Jul;27 Suppl 5(Suppl 5):24-35. doi: 10.1111/dom.16488. Epub 2025 Jun 4.
3
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.

本文引用的文献

1
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐:第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
2
Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit.评估改善1型和2型糖尿病成人患者血糖控制管理对临床并发症数量及相关经济效益的影响。
Diabet Med. 2016 Nov;33(11):1575-1581. doi: 10.1111/dme.13062. Epub 2016 Apr 15.
3
估算 2 型糖尿病患者的风险因素时间路径和风险因素管理的 QALY 收益。
Pharmacoeconomics. 2024 Sep;42(9):1017-1028. doi: 10.1007/s40273-024-01398-4. Epub 2024 Jun 26.
4
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data.评估 1 型糖尿病患者使用连续血糖监测的成本效用:使用决策模型或经验数据的研究方法和质量的系统评价。
Pharmacoeconomics. 2024 Sep;42(9):929-953. doi: 10.1007/s40273-024-01388-6. Epub 2024 Jun 21.
5
Health state utility values ranges across varying stages and severity of type 2 diabetes-related complications: A systematic review.健康状态效用值在 2 型糖尿病相关并发症的不同阶段和严重程度上存在差异:一项系统评价。
PLoS One. 2024 Apr 4;19(4):e0297589. doi: 10.1371/journal.pone.0297589. eCollection 2024.
6
A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus.糖尿病治疗模型中使用的方法学的系统评价。
Pharmacoeconomics. 2024 Jan;42(1):19-40. doi: 10.1007/s40273-023-01312-4. Epub 2023 Sep 22.
7
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus.新型非胰岛素抗糖尿病药物成本效益研究的系统评价:用于模拟 2 型糖尿病的决策分析模型的趋势。
Pharmacoeconomics. 2023 Nov;41(11):1469-1514. doi: 10.1007/s40273-023-01268-5. Epub 2023 Jul 6.
8
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry.SGLT2 抑制剂在真实世界人群中的成本效益:基于常规数据的 GP 注册处的 MICADO 模型分析。
Pharmacoeconomics. 2023 Oct;41(10):1249-1262. doi: 10.1007/s40273-023-01286-3. Epub 2023 Jun 10.
9
Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.司美格鲁肽与恩格列净、卡格列净和西他列汀治疗丹麦2型糖尿病患者的成本效益:一项决策分析模型研究
Pharmacoecon Open. 2023 Jul;7(4):579-591. doi: 10.1007/s41669-023-00416-z. Epub 2023 May 13.
10
Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.美国 1 型糖尿病患者管理中无管自动化胰岛素输送系统与标准治疗的成本效益比较。
J Manag Care Spec Pharm. 2023 Jul;29(7):807-817. doi: 10.18553/jmcp.2023.22331. Epub 2023 May 3.
Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.
糖尿病及其并发症的计算机建模:第五届胡德山挑战赛会议报告。
Value Health. 2013 Jun;16(4):670-85. doi: 10.1016/j.jval.2013.01.002. Epub 2013 Apr 18.
4
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.健康经济评估报告标准(CHEERS)——解释与说明:国际卫生经济学会健康经济评估报告指南良好报告实践工作组报告。
Value Health. 2013 Mar-Apr;16(2):231-50. doi: 10.1016/j.jval.2013.02.002.
5
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.模型透明度和验证:ISPOR-SMDM 建模良好实践工作组报告-7。
Med Decis Making. 2012 Sep-Oct;32(5):733-43. doi: 10.1177/0272989X12454579.
6
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.建立良好研究实践模型——概述:ISPOR-SMDM 建立良好研究实践工作组 1 的报告。
Med Decis Making. 2012 Sep-Oct;32(5):667-77. doi: 10.1177/0272989X12454577.
7
Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.糖尿病及其并发症的计算机建模:胡德山挑战赛第四次会议报告
Diabetes Care. 2007 Jun;30(6):1638-46. doi: 10.2337/dc07-9919.
8
Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.卫生技术评估中决策分析模型的良好实践指南:质量评估的综述与整合
Pharmacoeconomics. 2006;24(4):355-71. doi: 10.2165/00019053-200624040-00006.
9
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).2型糖尿病强化血糖控制与严格血压控制的成本效用分析(英国前瞻性糖尿病研究72)
Diabetologia. 2005 May;48(5):868-77. doi: 10.1007/s00125-005-1717-3. Epub 2005 Apr 15.
10
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).一种用于估计2型糖尿病患者终生健康结局的模型:英国前瞻性糖尿病研究(UKPDS)结局模型(UKPDS第68号)。
Diabetologia. 2004 Oct;47(10):1747-59. doi: 10.1007/s00125-004-1527-z. Epub 2004 Oct 27.